Investigating how B cell-targeted therapies can help prevent kidney transplant rejection in primates
Immune repertoire remodeling following B cell-targeted CAR T cells for induction of renal allograft tolerance in non-human primates
This study is looking at new treatments that target specific immune cells to help kidney transplants last longer without needing strong medications, which could make life easier for patients receiving transplants.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pennsylvania NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project ID | NIH-11108442 on NIH RePORTER |
What this research studies
This research explores the use of B cell-targeted therapies to induce tolerance in kidney transplants, aiming to prevent chronic immune rejection. By utilizing a combination of a CD20-specific antibody and T cell depletion, the study examines how these treatments can prolong the survival of kidney allografts in non-human primates. The approach focuses on understanding the immune response and the role of B cells in transplant acceptance, which could lead to less reliance on long-term immunosuppression. Patients may benefit from insights gained that could translate into improved kidney transplant outcomes.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals who have received or are considering kidney transplants and may be at risk for rejection.
Not a fit: Patients who are not candidates for kidney transplantation or those with conditions that contraindicate participation in experimental therapies may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective strategies for preventing kidney transplant rejection, reducing the need for lifelong immunosuppression.
How similar studies have performed: Previous studies have shown promise in using B cell-targeted therapies for transplant tolerance, indicating potential for success in this novel approach.
Where this research is happening
Philadelphia, United States
- University of Pennsylvania — Philadelphia, United States (Active)
Researchers
- Principal investigator: Naji, Ali — University of Pennsylvania
- Study coordinator: Naji, Ali
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.